Individualized treatment for allergic rhinitis based on key nasal clinical manifestations combined with histamine and leukotriene D4 levels.

Szczegóły
Abstrakt

Tytuł:: Individualized treatment for allergic rhinitis based on key nasal clinical manifestations combined with histamine and leukotriene D4 levels.
Autorzy:: Shen C; Department of Otorhinolaryngology Head and Neck Surgery, Southern Medical University, Zhujiang Hospital, Guangzhou, China.
Chen F; Department of Otorhinolaryngology Head and Neck Surgery, Southern Medical University, Zhujiang Hospital, Guangzhou, China.
Wang H; Department of Otorhinolaryngology Head and Neck Surgery, Southern Medical University, Zhujiang Hospital, Guangzhou, China.
Zhang X; Department of Otorhinolaryngology Head and Neck Surgery, Southern Medical University, Zhujiang Hospital, Guangzhou, China.
Li G; Department of Otorhinolaryngology Head and Neck Surgery, Southern Medical University, Zhujiang Hospital, Guangzhou, China.
Wen Z; Department of Otorhinolaryngology Head and Neck Surgery, Southern Medical University, Zhujiang Hospital, Guangzhou, China. Electronic address: .
Źródło:: Brazilian journal of otorhinolaryngology [Braz J Otorhinolaryngol] 2020 Jan - Feb; Vol. 86 (1), pp. 63-73. Date of Electronic Publication: 2018 Oct 24.
Typ publikacji:: Controlled Clinical Trial; Journal Article
Język:: English
Imprint Name(s):: Original Publication: São Paulo, SP, Brasil : E.N.T. Brazilian Society
MeSH Terms:: Drug Therapy, Combination/*methods
Histamine/*blood
Leukotriene D4/*blood
Precision Medicine/*methods
Rhinitis, Allergic/*blood
Acetates/therapeutic use ; Adolescent ; Adult ; Aged ; Anti-Allergic Agents/therapeutic use ; Cyclopropanes ; Female ; Humans ; Loratadine/therapeutic use ; Male ; Middle Aged ; Mometasone Furoate/therapeutic use ; Nasal Mucosa ; Nasal Obstruction/drug therapy ; Quinolines/therapeutic use ; RNA, Messenger/genetics ; Receptors, Histamine H1/genetics ; Receptors, Leukotriene/genetics ; Rhinitis, Allergic/diagnosis ; Rhinitis, Allergic/drug therapy ; Sneezing ; Sulfides ; Treatment Outcome ; Young Adult
References:: Ann Allergy. 1988 Jun;60(6):537-40. (PMID: 3382059)
Kulak Burun Bogaz Ihtis Derg. 2014 Jul-Aug;24(4):217-24. (PMID: 25046070)
Ann Allergy Asthma Immunol. 2010 Aug;105(2):155-61. (PMID: 20674827)
Allergy. 2008 Apr;63 Suppl 86:8-160. (PMID: 18331513)
Immunity. 2012 Mar 23;36(3):451-63. (PMID: 22425247)
J Allergy Clin Immunol. 2013 Jan;131(1):144-9. (PMID: 23040367)
Allergy Asthma Proc. 2008 Mar-Apr;29(2):140-5. (PMID: 18430310)
Nature. 2008 Jul 24;454(7203):445-54. (PMID: 18650915)
N Engl J Med. 1999 Jan 21;340(3):197-206. (PMID: 9895400)
Ann Allergy Asthma Immunol. 2006 Jun;96(6):779-86. (PMID: 16802764)
Otolaryngol Head Neck Surg. 2015 Feb;152(1 Suppl):S1-43. (PMID: 25644617)
Allergy. 2005 Jul;60(7):882-7. (PMID: 15932377)
Allergol Int. 2014;63(3):357-375. (PMID: 28942929)
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2014 Aug;49(8):659-67. (PMID: 25351124)
Allergy. 2001;56 Suppl 66:7-11. (PMID: 11421935)
Indian J Otolaryngol Head Neck Surg. 2013 Aug;65(Suppl 2):333-7. (PMID: 24427672)
J Allergy Clin Immunol. 2002 Jun;109(6):949-55. (PMID: 12063523)
Forensic Sci Int. 2011 Oct 10;212(1-3):96-101. (PMID: 21664082)
Curr Allergy Asthma Rep. 2013 Apr;13(2):203-8. (PMID: 23389557)
J Immunol Res. 2015;2015:384780. (PMID: 25918735)
J Immunol. 2009 Jan 15;182(2):1119-28. (PMID: 19124755)
J Laryngol Otol. 2014 Mar;128(3):242-8. (PMID: 24618303)
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009 Dec;44(12):977-8. (PMID: 20193608)
J Allergy Clin Immunol. 2003 Jul;112(1):15-22. (PMID: 12847474)
Clin Exp Allergy. 2003 Oct;33(10):1380-8. (PMID: 14519144)
Pharmacol Res. 2004 Jul;50(1):1-11. (PMID: 15082024)
Neuropharmacology. 2016 Jul;106:56-73. (PMID: 26581501)
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2005 Mar;40(3):166-7. (PMID: 15952561)
Am J Rhinol. 2005 Nov-Dec;19(6):591-8. (PMID: 16402647)
Auris Nasus Larynx. 2008 Mar;35(1):61-6. (PMID: 17826020)
J Allergy Clin Immunol. 2005 Jul;116(1):80-7. (PMID: 15990778)
Chest. 2001 May;119(5):1533-46. (PMID: 11348965)
Otolaryngol Head Neck Surg. 2003 Sep;129(3):274-9. (PMID: 12958580)
J Allergy Clin Immunol. 2012 Nov;130(5):1049-62. (PMID: 23040884)
Contributed Indexing:: Keywords: Allergic rhinitis; Clinical typing; Histamina; Histamine; Individualized treatment; Leucotrienos; Leukotrienes; Rinite alérgica; Tipificação clínica; Tratamento individualizado
Substance Nomenclature:: 0 (Acetates)
0 (Anti-Allergic Agents)
0 (Cyclopropanes)
0 (Quinolines)
0 (RNA, Messenger)
0 (Receptors, Histamine H1)
0 (Receptors, Leukotriene)
0 (Sulfides)
04201GDN4R (Mometasone Furoate)
73836-78-9 (Leukotriene D4)
7AJO3BO7QN (Loratadine)
820484N8I3 (Histamine)
LRF7RW46ID (leukotriene D4 receptor)
MHM278SD3E (montelukast)
Entry Date(s):: Date Created: 20181124 Date Completed: 20200415 Latest Revision: 20220902
Update Code:: 20240105
PubMed Central ID:: PMC9422539
DOI:: 10.1016/j.bjorl.2018.09.007
PMID:: 30467056
: Czasopismo naukowe

Full Text Finder

Introduction: The types of allergic rhinitis are roughly classified based on the causative antigens, disease types, predilection time, and symptom severity.
Objective: To examine the clinical typing and individualized treatment approach for allergic rhinitis and to determine the optimal treatment method for this disease using various drug combination therapies.
Methods: A total of 108 participants with allergic rhinitis were divided into three groups based on symptoms. Subsequently, each group was further categorized into four subgroups based on the medications received. The efficacy of the treatments was evaluated using the visual analog scale VAS scores of the total and individual nasal symptoms, decline index of the symptom score, histamine and leukotriene levels, and mRNA and protein expression levels of histamine 1 and cysteinyl leukotriene 1 receptors.
Results: Loratadine+mometasone furoate and loratadine+mometasone furoate+montelukast significantly improved the sneezing symptom and reduced the histamine levels compared with the other combination therapies (p<0.05). Meanwhile, montelukast+mometasone furoate and montelukast+mometasone furoate+loratadine considerably improved the nasal obstruction symptom and decreased the leukotriene D4 levels compared with the other combination therapies (p<0.05).
Conclusion: Clinical symptom evaluation combined with experimental detection of histamine and leukotriene levels can be an objective and accurate method to clinically classify the allergic rhinitis types. Furthermore, individualized treatment based on allergic rhinitis classification can result in a good treatment efficacy.
(Copyright © 2018 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Published by Elsevier Editora Ltda. All rights reserved.)

Informacja